C3-R: the present and the future


You can leave the epithelium intact, say Dr Roberto Pinelli and Dr Tarek El Beltagi

Key Points

It was Professor Theo Seiler who first proposed applying the principally dental and orthopaedic concept of cross-linking to corneal collagen fibres as a treatment for ectasia; specifically, keratoconus (KC).

The procedure works because a combined use of riboflavin (vitamin B2) and ultraviolet-A (UV-A) irradiation induces a strengthening of corneal stroma, by creating, between the collagen fibres, new stromal bonds as a result of the UV-A radiation's effect on the unstable riboflavin molecule.

It was initially believed that the C3-R treatment required epithelial debridement to improve riboflavin penetration in the stroma, although more recently the treatment may be performed with the epithelium left intact. There remain differing opinions regarding the removal of the epithelium (or not): there are those who believe that, with the epithelium left on, the penetrating capability of riboflavin could be slower and the treatment less efficacious.

Can we prove it?

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Dr Richard Lindstrom, Chairman of Surface Ophthalmics and founder of Minnesota Eye Consultants, speaks about ASCRS
Dr Adam Muzychuk discusses his ASCRS presentation
© 2024 MJH Life Sciences

All rights reserved.